Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
Albany, New York (PRWEB) March 16, 2013
The growth of the market is driven by factors such as rising incidences of cardiovascular diseases, metabolic diseases and technological enhancement in peptide synthesis. The Asian region offers future growth prospects to the peptide industry owing to vast unmet medical needs and rising disposable income of patients.
Related Report : Antibody Drugs Market,
Amongst the application market, the cancer peptide segment accounted for the largest share of approximately 21% and is expected to grow at a healthy CAGR during the forecast period. The neuropeptides application segment is anticipated to grow at a CAGR of 9.4% from 2012 to 2018 due to the rise in number of neurological disorders such as Alzheimer's and Parkinson's disease.
The parenteral route of administration of peptides accounted for the largest share of around 86% in year 2011, in terms of routes of administration; however other routes of administration like oral, pulmonary, nasal and intradermal are also being tested and are estimated to experience healthy growth rate during the forecast period.
Related Report : Kinase Inhibitors Market
Technological enhancement with introduction of hybrid technology along with solid phase peptide syntheses (SPPS) is expected to enhance the growth of peptide therapeutics. The hybrid technology segment which provides the best of both solid and liquid syntheses is now being adopted by major players and hence this market is expected to see the highest growth of 12.1% from 2012 to 2018.
Browse the full report with TOC at http://www.transparencymarketresearch.com/peptide-therapeutics-market.html
The North American peptide therapeutics market held majority of the market share of approximately 40% in 2011 owing to its developed economy. However, due to rise in cost containment and budgetary cuts in North America, emerging countries such as India, China and other Latin American countries is expected to see a healthy growth in the study period.
Some of the key market players are Eli Lilly, Roche, Amylin, Novo-Nordisk, Ipsen and others. The contract manufacturing organization (CMO) industry includes major players such as Bachem, Polypeptide Group, Lonza, Peptisyntha and others.
Browse All Market Research Reports : http://www.transparencymarketresearch.com/